Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856142 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNARAB9ANPC1HPGD | |
| SCHEMBL4823240 | 0.86 | HPGD (0.68) | SMN1; SMN2LMNARAB9ANPC1HPGD | |
| SCHEMBL3560486 | 0.80 | POLB (0.73) | SMN1; SMN2LMNARAB9ANPC1HPGD | |
| SCHEMBL11118147 | 0.80 | RAB9A (0.56) | SMN1; SMN2LMNARAB9ANPC1HPGD | |
| SCHEMBL134279 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNARAB9ANPC1HPGD | |
| SCHEMBL5218226 | 0.79 | HPGD (0.44) | SMN1; SMN2LMNARAB9ANPC1HPGD | |
| SCHEMBL27183334 | 0.78 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNARAB9ANPC1HPGD | |
| SCHEMBL10191948 | 0.77 | HPGD (0.46) | SMN1; SMN2LMNAHPGDCYP1A2CYP2C9 | |
| SCHEMBL8301733 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNARAB9ANPC1HPGD | |
| SCHEMBL1726857 | 0.76 | LMNA (0.76) | SMN1; SMN2LMNARAB9APOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | SMN1; SMN2 2166/4885LMNA 1762/4885RAB9A 2051/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | SMN1; SMN2 2166/4885LMNA 1762/4885RAB9A 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.